Aurora shareholders get an offer from Organigram, 93% above the price before Curaleaf's bid.
Organigram to acquire Aurora for C$7.80 per share, a 93% premium over Aurora's unaffected price. The deal, supported by both boards, values Aurora at approximately C$1.33B. Aurora shareholders can choose cash, shares, or a mix. The combined company aims to enhance scale, supply chain, and global footprint. Organigram's significant shareholder, BAT, will participate in financing.
How this was made
The 30-second read
Why it matters
For Aurora, the offer frames a higher, structured value alternative to the rejected hostile bid. For Organigram, the deal is positioned as a scale and supply-chain certainty play, financed through cash, BAT investment, and credit facility, but remains subject to shareholder votes and deal completion risks.
Market read
This is a primary M&A disclosure with explicit consideration terms and a stated premium versus both an unaffected price and an earlier hostile bid, making it directly tradable for deal-premium and spread dynamics.
What to watch
Key sensitivities include financing terms beyond “cash on hand, BAT investment, and credit facility,” potential dilution from share consideration, and how the combined entity’s EU-GMP and distribution footprint translates into near-term margin and cash-flow improvements.
Background
The article describes a proposed acquisition of Aurora by Organigram, including cash/share election mechanics, board support, and references to an earlier unsolicited Curaleaf hostile bid.
Ticker impact
Aurora shareholders are offered an Organigram acquisition price per Aurora share, including cash or Organigram shares, with the board unanimously rejecting a prior Curaleaf bid.
Likely upward bias as the market prices in a higher, structured value offer, tempered by deal uncertainty and shareholder vote/proration mechanics.
The article discloses a specific acquisition consideration and references a rejected hostile bid, which typically improves near-term valuation while still leaving regulatory and shareholder approval as key overhangs.
Organigram proposes to acquire Aurora for consideration per Aurora share, financed via cash on hand plus BAT investment and credit facility, with both boards supporting.
Likely mixed-to-positive reaction as the market weighs strategic scale benefits against dilution and integration risks.
The text provides deal structure, financing sources, and board support, but does not provide pro forma valuation metrics or deal-breaker regulatory outcomes.
Market effects
Signals consolidation in global cannabis manufacturing and distribution, potentially reshaping competitive positioning around EU-GMP capacity and cross-border brands.
Could shift bargaining power and supply-chain certainty across Canada, Europe, Australia, and New Zealand cannabis markets.
Creates a larger cross-border cannabis platform with stated global footprint and diversification, relevant to international investors tracking sector consolidation.
Counterpoint
The premium may not fully de-risk outcomes because the article highlights a previously rejected hostile bid and implies complex proration, voting thresholds, and regulatory approvals that can still derail timing or economics.
Key entities
- companyAurora Cannabis
Target company whose shareholders receive an offer from Organigram with cash, Organigram shares, or a combination, subject to proration and special-meeting votes.
- companyOrganigram
Acquirer proposing to acquire Aurora via a court-approved plan of arrangement, with stated financing sources and board support.
- companyCuraleaf
Referenced as having made an unsolicited hostile bid whose implied value is cited for comparison, and which Aurora’s board rejected.
- companyBAT
Referenced as a strategic shareholder supporting financing and bringing R&D and global supply chain expertise to the combined company.
